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Abstract
Parkinson’s disease is the most common neuro-degenerative movement disorder. α-Synuclein is a
small synaptic protein that has been linked to familial Parkinson’s disease (PD) and is also the
primary component of Lewy bodies, the hallmark neuropathology found in the brain of sporadic
and familial PD patients. The function of α-synuclein is currently unknown, although it has been
implicated in the regulation of synaptic vesicle localization or fusion. Recently, overexpression of
α-synuclein was shown to cause cytoplasmic vesicle accumulation in a yeast model of α-synuclein
toxicity, but the exact role α-synuclein played in mediating this vesicle aggregation is unclear.
Here, we show that α-synuclein induces aggregation of many yeast Rab GTPase proteins, that α-
synuclein aggregation is enhanced in yeast mutants that produce high levels of acidic
phospholipids, and that α-synuclein colocalizes with yeast membranes that are enriched for
phosphatidic acid. Significantly, we demonstrate that α-synuclein expression induces vulnerability
to perturbations of Ypt6 and other proteins involved in retrograde endosome–Golgi transport,
linking a specific trafficking defect to α-synuclein phospholipid binding. These data suggest new
pathogenic mechanisms for α-synuclein neurotoxicity.
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Introduction
Parkinson’s disease (PD) is characterized clinically by bradykinesia, resting tremor, stooped
posture, and rigidity (Galvin et al. 2001). Lewy bodies (LBs), the hallmark lesions found in
the brain of patients with PD, are composed of α-synuclein amyloid fibrils (Spillantini et al.
1997), and α-synuclein can form similar fibrils in vitro in a time and concentration-
dependent manner (Conway et al. 1998; Giasson et al. 1999; Wood et al. 1999). The
identification of point mutations, i.e. A53T, A30P, and E46K, as well as duplications and
triplications in the α-synuclein gene in early onset familial PD (Polymeropoulos et al. 1997;
Kruger et al. 1998; Singleton et al. 2003; Chartier-Harlin et al. 2004; Zarranz et al. 2004)
support a pivotal role for α-synuclein in the etiology and pathogenesis of PD. For example,
mutations associated with early onset familial PD accelerate in vitro fibril formation
(Conway et al. 1998; Li et al. 2002; Greenbaum et al. 2005), and transgenic mice
overexpressing mutant A53T α-synuclein developed motoric phenotypes and LB-like
inclusions (Giasson et al. 2002; Lee et al. 2002). These observations suggest that α-
synuclein is directly involved with the pathogenesis of PD and strongly implicates fibril
formation as a pathogenic mechanism.
α-Synuclein is a 140 amino acid protein of unknown function that localizes to synaptic
vesicles in rat brain (Jakes et al. 1994; Iwai et al. 1995). The N terminus of α-synuclein
contains six imperfect repeats of the KTKEGV motif which resembles the lipid binding
domain of apolipoproteins (Segrest et al. 1992) and adopts an α-helical structure that
facilitates membrane binding when in the presence of acidic phospholipids (Jensen et al.
1998; Perrin et al. 2000; Jao et al. 2004; Kubo et al. 2005; Kim et al. 2006; Stockl et al.
2008). Although α-synuclein knockout mice are viable with no abnormal brain morphology,
these animals exhibit reduced levels of striatal dopamine and an attenuated response to
amphetamine (Abeliovich et al. 2000; Yavich et al. 2004). Moreover, cultured hippocampal
neurons from α-synuclein knockout mice have a decreased reserve pool of synaptic vesicles,
as well as a decrease in the number of docked vesicles (Cabin et al. 2002). These data
suggest that α-synuclein regulates synaptic vesicle trafficking at the synapse. Consistent
with these observations, α-synuclein overexpression in PC12 cells results in an increase in
docked vesicles at the synapse, further supporting the role of α-synuclein in vesicle tethering
to the presynaptic plasma membrane (Larsen et al. 2006). In this regard, α-synuclein
compensates for the loss of cysteine string protein-α (CSPα), a synaptic chaperone, and
rescues deficits in SNARE complex assembly in CSPα knockout mice (Chandra et al. 2005)
and antagonizes SNARE function in mammalian cells (Thayanidhi et al. 2010). The
relationship between the ability of α-synuclein to regulate the synaptic vesicle cycle and the
progression of human disease is currently unknown.
We previously reported a vesicle accumulation phenotype in Saccharomyces cerevisiae
overexpressing human α-synuclein (Soper et al. 2008). This morphological phenotype is
accompanied by cellular toxicity and disruption of Golgi organization and requires the
integrity of both the α-synuclein N-terminal and central hydrophobic regions (Volles and
Lansbury 2007; Soper et al. 2008). The accumulated vesicular structures contain membrane-
associated α-synuclein and sequester the yeast Rab GTPase proteins Ypt1 and Sec4 (Gitler
et al. 2008; Soper et al. 2008). Because of the suspected role of α-synuclein in regulation of
the synaptic vesicle cycle, and the known involvement of Rab GTPases as regulators of
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vesicle tethering and fusion, we further characterized this vesicle aggregation phenotype.
We now demonstrate that functional ablation of the Rab GTPase Ypt6, as well as of other
endosomal Rab GTPases, cause a significant increase in vesicle aggregation and toxicity.
Furthermore, we demonstrate that yeast cells expressing α-synuclein are sensitive to
disruption of endosome–Golgi retrograde trafficking pathways and that this sensitivity is
correlated with enhanced vesicle accumulation and toxicity. Finally, we demonstrate α-
synuclein associates with phosphatidic acid-rich membranes in yeast, and yeast mutants that
accumulate acidic phospholipids show a more severe vesicle clustering phenotype. Taken
together, these findings are consistent with the idea that α-synuclein associates with Golgi-
endosomal membranes in a phosphatidic acid-sensitive manner and that excessive
membrane binding by α-synuclein interferes with specific vesicle trafficking pathways with
resulting cell toxicity.
Materials and Methods
Yeast Strains and Media
The strains CTY182 (MATa, ura3-52, Δhis3-200, lys2-801am), CTY1-1A (MATa, ura3-52,
Δhis3-200, lys2-801am, sec14-1ts), CTY159 (MATa, ura3-52, Δhis3-200, lys2-801am,
sec14-1ts, kes1-1), and CTY160 (MATa, ura3-52, Δhis3-200, lys2-801am, sec14-1ts, cki1-1)
were used for phospholipid studies. The BY4741 (MATa, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0)
and its associated deletion mutants (Brachmann et al. 1998) were used for all other
experiments in this study. Transformation of yeast was performed using a standard lithium
polyethylene glycol transformation procedure (Gietz et al. 1997). Yeast cultures were grown
in selective minimal media, containing 2% glucose or 2% galactose, deficient in the required
amino acids. For induction of gene expression, cells were cultured in glucose media
overnight, and cells from this culture were taken to inoculate a second culture (starting
A600=0.1) in galactose media, which was then grown at 30°C for 16 h.
Plasmids and Constructs
Integrative α-synuclein-EGFP constructs were generated as previously described (Soper et
al. 2008). Briefly, integrative strains were generated by PCR amplification of the Gal1
promoter, α-syn-EGFP protein sequence, transcription terminator, and selection marker
sequence out of the PYES2 vector. Primer sequences were chosen for directed integration
into the yeast genome 500 bp upstream of the Gal1 promoter. N-terminal RFP-tagging
vectors were generated by PCR cloning of the mcherry RFP (Shaner et al. 2004) sequence
with ablation of the stop codon into the pRS 415 vector (ATCC) with either the Ypt1,
alcohol dehydrogenase (ADH), or glyceraldehydes-3-phosphate dehydrogenase promoter
sequences. Yeast Rab GTPases were PCR cloned and inserted in frame downstream of the
RFP sequence. All vectors were sequenced and confirmed before use. The P423 TEF RFP-
Spo2051–91 vector (Nakanishi et al. 2004) was kindly donated by Dr. Aaron Neiman
(Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY
11794, USA).
Phosphatidic Acid Quantification
Yeast cell cultures were incubated under the appropriate conditions in selective minimal
media, pelleted, washed twice with ice-cold water, and the pellets containing 5×106 cells
flash frozen in liquid nitrogen. Phospholipids were extracted from the cell pellets, prepared
for analysis, and phosphatidic acid quantified by mass spectrometry as described (Ivanova et
al. 2007). Data were normalized against an internal phosphatidic acid standard marked by its
odd number acyl-chain carbon property (Ivanova et al. 2007).
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Growth was measured on solid media by making serial five-fold dilutions of log-phase
cultures, starting with A600 =1.0. Samples of each dilution were spotted onto minimal media
glucose and galactose plates, with appropriate amino acids for selection. Plates were
incubated at 30°C for 2–4 days.
Immunoblot Analysis
Cell extracts were prepared as described previously (Kushnirov 2000). Briefly, cells were
grown in galactose media to log-phase. Equal amounts of cells were pelleted by
centrifugation, resuspended in one volume water and treated with one volume 0.2 M NaOH
for 10 min. Cells were pelleted again, resuspended in SDS/PAGE buffer, and boiled for 5
min and protein samples were separated by SDS/PAGE. For immunoblotting, we used
LB509, an anti-α-syn mouse mAb recognizing residues 115–122 (Jakes et al. 1999), SNL-1,
an affinity-purified rabbit polyclonal α-synuclein antibody raised to amino acid residues
104–119 of α-syn (Giasson et al. 2000), monoclonal and polyclonal DsRed antibodies
(Clontech), and 6C5, a monoclonal GAPDH antibody (Advanced ImmunoChemical Inc.).
Fluorescence Microscopy and Quantification
Cells were grown in galactose minimal media for 16 h and fixed in 4% paraformaldehyde in
40 mM phosphate buffer for 1 h at 30°C. Cells were then washed twice in 40 mM phosphate
buffer and mounted on PDL coated dishes for microscopy. Images were captured on a Nikon
TE-2000-E (Nikon, Japan) inverted epifluorescence microscope. Typically, the exposure
time was between 100 and 2,000 ms, with the camera (CoolSnap-HQ, Photometrics, Tucson,
AZ) operating at maximum gain. Images were typically captured at ×60 or ×100
magnification. All image acquisition and processing was done using Metamorph (Molecular
Devices, Downingtown, PA). All images were scaled linearly in Metamorph and
subsequently mounted in Adobe photoshop (Adobe, San Jose, CA) for display.
Quantification of accumulations was done by capturing images of cultures that had been
grown in galactose media for 16 h. Twenty representative fields from four separate cultures
were counted, with approximately 250 cells in each field, and cells were scored for presence
of accumulations.
Protein Extraction, Immunoprecipitation, and Metabolic Labeling
Yeast cultures were grown in galactose media to log phase. Samples were washed once in
20 mM Hepes, pH 7.5, 20 mM NaF, 20 mM NaN3, and resuspended in RSB100 buffer (20
mM Tris, 2.5 mM MgCl2, 100 mM NaCl, 0.1 mM PMSF, pH 7.4, with protease inhibitors).
Cells were lysed by vortexing for 10 min with acid-washed glass beads. Samples were
centrifuged at 1,200×g for 4 min; the supernatant was centrifuged again at 1,200×g for 4
min, and then used for immunoprecipitation (IP).
For IP, 50 μL protein A/G beads were incubated with 10 μg of Syn211, an anti-α-synuclein
mAb (Giasson et al. 2000), or T14, an anti-tau mAb, for 1 h at 4°C in 500 μL RSB100
buffer. Beads were washed twice in RSB100 buffer, 20 μg yeast cell extract was added to
each IP reaction, and the IP sample was incubated for 1 h at 4°C. Beads were then washed
five times, keeping the initial flow through, and resuspended in 50 μL SDS sample buffer
for SDS–PAGE.
For metabolic labeling, yeast cultures were grown to log phase in galactose media, washed
once with and resuspended in galactose media devoid of Uracil (Ura) and Methionine (Met);
0.5 mCi of [35S]-Met was added, and cultures were grown an additional 2 h at 30°C.
Samples were then centrifuged and washed once in galactose media without Ura and Met,
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then washed in RSB100. Protein extraction and immunoprecipitation were then performed
as described above, except 200 μg cell extract was used in each IP. SDS–PAGE was
performed on a 5–20% tris-glycine gradient gel, fixed in 40% methanol, 10% acetic acid for
20 min. The gel was dried and exposed to a phosphoimager plate for 1 week.
Statistical Analyses
Comparison of sample means and calculation of P values were performed using GraphPad
Prism 4.0 software.
Results
Expression of α-Synuclein Disrupts Localization of Rab GTPase Proteins in S. cerevisiae
Previous studies identified two Rab GTPase proteins, Sec4p and Ypt1p, that colocalize with
α-synuclein in vesicle aggregates (Soper et al. 2008). To further evaluate if other Rab
GTPases are also involved in α-synuclein-mediated vesicle aggregation, RFP-tagged Rab
GTPase proteins were expressed under control of the constitutive ADH promoter in yeast
coexpressing Syn-EGFP. The ADH promoter drove physiological levels of Ypt1p
expression and the Ypt1 localized properly to endoplasmic reticulum (ER)-to-Golgi vesicles
(Figure S1).
Surprisingly, all nine of the yeast Rab GTPase proteins that we examined colocalized with
Syn-EGFP-labeled vesicle aggregates. This was judged to be a specific effect as RFP alone
(Fig. 1a) and RFP-Vma4p (Fig. 1b), a subunit of the membrane domain of the vacuolar
ATPase (Foury 1990), retained cytoplasmic and vacuole membrane labeling, respectively, in
cells expressing EGFP or Syn-EGFP. As expected, RFP-Sec4p (Fig. 1c) localized to
punctate secretory structures at the bud neck in EGFP cells (Guo et al. 1999) and colocalized
with Syn-EGFP-positive puncta in Syn-EGFP cells, verifying that the RFP fusion protein
behaves similarly to the HA-tagged protein. However, despite the mislocalization to vesicle
aggregates, some RFP-Sec4p is still localized to the bud neck of Syn-EGFP expressing cells
suggesting that it is localized correctly (Fig. 1c, arrow). Similar to previous reports, RFP-
Ypt1p localized to punctate Golgi structures in EGFP cells, and colocalized with Syn-EGFP
accumulations (Fig. 1d). We also observed colocalization between α-synuclein and Rab-
GTPases involved in retrograde endosome–Golgi transport (Ypt6p, Fig. 1e) (Luo and
Gallwitz 2003), endosome–vacuole transport and vacuolar inheritance (Ypt7p, Fig. 1f)
(Wichmann et al. 1992; Schimmoller and Riezman 1993), the endocytic pathway (Ypt10p,
Ypt51p, Ypt53p; Fig. 1g, j, k) (Singerkruger et al. 1994; Frei et al. 2006), and Golgi and
post-Golgi trafficking (Ypt31p, Ypt32p; Fig. 1h, i) (Benli et al. 1996). Localization of RFP-
Ypt10p to the vacuole membrane was still observed despite Ypt10p mislocalization,
indicating that it may still be capable of performing its normal function in Syn-EGFP
expressing cells (Fig. 1g, arrow). The proper localization of Ypt10p, as well as Vma4p,
indicates that despite the mislocalization of many Rab-GTPase proteins onto large
aggregates of cytoplasmic vesicles, protein trafficking to the vacuolar membrane was not
obviously perturbed.
Yeast Rab GTPases may be targeted to vesicle aggregates by direct interactions between α-
synuclein and Rab GTPase proteins. To examine if there is a direct interaction between Rab
GTPases and α-synuclein in yeast, we performed co-immunoprecipitation experiments with
α-synuclein-EGFP and RFP-labeled Rab GTPases. Using Syn211, a C-terminal α-synuclein
mAb, to immunoprecipitate α-synuclein-EGFP from yeast extracts, we were unable to detect
a direct interaction between α-synuclein and RFP-Ypt6, RFP-Sec4 (Figure S2A), RFP-Ypt7,
or RFP-Ypt31 (data not shown). Moreover, we were unable to identify unique proteins that
specifically co-immunoprecipitate with α-synuclein from [35S]-Met radiolabeled yeast cells
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(Figure S2B). These data suggest that α-synuclein induces accumulation and mislocalization
of many Rab GTPase proteins in yeast without a requirement for stable, direct physical
interactions. Rather, α-synuclein may exert this effect by interfering with vesicular
trafficking events.
Ypt6p Defects Enhance α-Synuclein-Induced Vesicle Aggregation
The mislocalization of Rab GTPases to vesicle aggregates may reflect either deranged
cycling of Rabs on/off of vesicle membranes or may report a Rab requirement for clustering
of these vesicles. To distinguish between these two possibilities, we examined vesicle
aggregation in yeast mutants genetically ablated for particular Rab GTPase activities or for
the activities of selected components of the vesicle trafficking machinery. Yeast knockout
strains expressing Syn-EGFP were induced for 20 h, and the fraction of cells containing
vesicle aggregations was quantified (Fig. 2a). Functional ablation of Ypt6p evoked a four-
fold increase in the proportion of Syn-EGFP-expressing cells containing vesicle
aggregations (19.22± 1.43% in control vs. 75.05±1.65% in ypt6Δ), while Ypt7p or Ypt51p
inactivation supported a mild increase in vesicle aggregation (33.81±2.189% in ypt7Δ,
42.98±2.932% in ypt51Δ). Similarly, inactivation of Gyp8p, a Rab GTPase activating
protein, resulted in a mild increase in vesicle aggregations. This effect may reflect its potent
ability to accelerate Ypt6p GTP hydrolysis, although Ypt1p, Sec4p Ypt31p, and Ypt32p are
also substrates for Gyp8p (De Antoni et al. 2002). Inactivation of the Ypt10p, Ypt31p,
Ypt32p, Ypt52p, or Ypt53p RabGTPases had no effect on Syn-EGFP-induced vesicle
aggregation. Similarly, deficiencies in Cdc50p (an endosomal protein involved in polarized
growth; Misu et al. 2003), Rcy1p (a protein involved in plasma membrane protein recycling
and early endocytosis; Wiederkehr et al. 2000), or Snc1p, a v-SNARE involved in secretory
vesicle fusion with the plasma membrane; Protopopov et al. 1993), had no effect on vesicle
aggregation in Syn-EGFP-expressing cells (Fig. 2a).
Western blot analyses (Fig. 2b) indicated that the increase in vesicle aggregation in ypt6Δ
mutants was not the trivial consequence of increased α-synuclein-EGFP expression. Rather,
the increased vesicle aggregation may be the indirect consequence of increased vesicle
content in the cytoplasm of these deletion mutants. Consistent with this possibility, yeast
deficient in Ypt6p (Tsukada and Gallwitz 1996) and Ypt51p (Singerkruger et al. 1994) do
exhibit increased numbers of cytoplasmic vesicles. However, Snc1p defects also result in an
increased load of cytoplasmic vesicles (Grote et al. 2000); yet, no effect on α-synuclein-
induced vesicle aggregation was observed in Snc1p-deficient yeast. We were unable to
assess the effect of Sec4p and Ypt1p, as these proteins perform essential housekeeping
functions and knockout of these genes are lethal. However, it is unlikely that the secretory
vesicle fusion step plays a vital role in vesicle aggregation, as snc1Δ yeast did not show a
significant increase in vesicle aggregation. Figure S3 presents a schematic of Rab GTPases
that we identified to be involved in α-synuclein-induced vesicle aggregation.
To further confirm the role Ypt6 played in α-synuclein-induced vesicle aggregation, we
asked if RFP-Ypt6p expression in ypt6Δ cells could rescue the enhanced vesicle aggregation
phenotype (Fig. 2c, d). As expected, ectopic RFP-Ypt6p expression-reduced vesicle
aggregation down to the level exhibited by control cells (13.50±1.25% in control Syn-EGFP
+RFP, 60.59±2.29% in ypt6Δ Syn-EGFP+RFP, 15.07±0.86% in ypt6Δ Syn-EGFP+RFP-
Ypt6p). Expression of the negative controls, RFP and RFP-Vma4p, failed to exert rescue.
Moreover, Ypt6p-deficient cells are exquisitely sensitive to Syn-EGFP expression, and this
sensitivity was also remedied by RFP-Ypt6p production (Fig. 2e). To examine if Ypt6p
expression in otherwise wild-type yeast expressing Syn-EGFP reduces vesicle aggregation,
yeast cells were cultured in 5% DMSO to elevate basal levels of vesicle aggregation. Under
these conditions, expression of RFP-Ypt6p, but not RFP alone, lowered the fraction of cells
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exhibiting vesicle aggregations from 41.04±1.12% to 21.74±1.15% (Fig. 2f). This effect was
not due to reduced Syn-EGFP expression levels (Fig. 2g).
Taken together, these data implicate Ypt6p as a significant regulator of α-synuclein-induced
formation of vesicle aggregations. Not only does Ypt6 dysfunction enhance vesicle
aggregation and sensitize cells to Syn-EGFP but also ectopic expression of Ypt6p protects
cells against α-synuclein-induced vesicle accumulation.
Disruption of Endosome-Golgi Retrograde Transport Increases Formation of α-Synuclein-
Induced Vesicle Aggregations and Toxicity
Ypt6p exchanges bound GDP for GTP in a reaction catalyzed by a heterodimer of two
proteins, Ric1p and Rgp1p (Siniossoglou et al. 2000). As shown in Fig. 3a and d, enhanced
Syn-EGFP-dependent vesicle aggregation was observed in both ric1Δ and rgp1Δ mutants
(9.04±0.48% in control vs 55.71±1.60% in ric1Δ and 52.25±2.56% in rgp1Δ). Functional
ablation of Gyp6p, a GTPase activating protein (GAP) for Ypt6p (Strom et al. 1993),
exerted a modest diminution in the efficiency of Syn-EGFP-induced vesicle aggregation.
The weakness of the effect may reflect the involvement of other GAPs in promoting GTP
hydrolysis by Ypt6p (Albert and Gallwitz 1999; Vollmer et al. 1999; De Antoni et al. 2002).
Ypt6p regulates fusion of endocytic vesicles with late Golgi compartments through its
functional interaction with the Golgi-associated retrograde protein (GARP) complex. The
GARP complex is composed of the Vps51p, Vps52p, Vps53p, and Vps54p subunits
(Siniossoglou and Pelham 2001), and dual inactivation of Vps51p and Ypt6p is incompatible
with cell viability (Tong et al. 2004). We therefore examined vesicle aggregation in GARP-
deficient cells producing Syn-EGFP. Indeed, large increases in formation of vesicle
aggregates were scored in the GARP mutants (40.18±2.98% for vps51Δ, 49.62±1.70% for
vps52Δ, vps53Δ data not shown, and 41.5 6±1.29% for vps54Δ; Fig. 3a). The enhanced
vesicle aggregation phenotypes were accompanied by enhanced sensitivity of these mutants
to Syn-EGFP expression (Fig. 3b). Again, we did not observe an increase in Syn-EGFP
expression level (Fig. 3c).
Several other known Ypt6p interactors were examined, including Imh1p, a Golgi-associated
coiled-coil protein containing a GRIP Golgi localization domain that is synthetically lethal
with Ypt6p deletions (Munro and Nichols 1999), andNhx1p, an endosomal Na+/H+
exchanger whose dysfunction results in inefficient vesicular trafficking from the prevacuolar
compartment (Bowers et al. 2000) and, interestingly, alleviates the temperature sensitive
growth deficits of ypt6Δ mutants. Ablation of either Imh1p or Nhx1p did not exert a
significant effect on vesicle aggregation in, or growth of, yeast expressing α-synuclein (Fig.
3a, b). Functional ablation of Vps35p, a component of the retromer protein complex
required for cargo retrieval from endosomes to the Golgi (Nothwehr et al. 2000), resulted in
only a mild increase in vesicle aggregation (9.04±0.48% in control, 22.03±1.62% in vps35Δ)
without an increase in cell sensitivity to Syn-EGFP expression (Fig. 3a, b). These modest
effects were recorded even though vps35Δ is synthetically lethal with ypt6Δ (Luo and
Gallwitz 2003), Therefore, some (Ric1p, Rgp1p, Vps51p), but not all (Imh1p, Vps35p),
components required for cell viability in the face of Ypt6p dysfunction are also sensitized to
α-synuclein expression. Likewise, several deficiencies that are tolerated by Ypt6p-deficient
yeast (i.e., Vps52, Vps54) are highly sensitized to the presence of α-synuclein. These data
suggest that α-synuclein does not have a direct inhibitory effect on Ypt6p, but instead affects
Ypt6p-regulated fusion process.
Fusion of endosomes to late Golgi compartments requires an interaction between the Ypt6/
GARP protein complex and the essential t-SNARE Tlg1p (Siniossoglou and Pelham 2002).
Tlg2p, a related Golgi t-SNARE, forms a SNARE complex with Tlg1p (Coe et al. 1999) and
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is also involved in endosome–Golgi fusion (Abeliovich et al. 1999). Tlg2p itself is not
essential for yeast viability, however. Syn-EGFP expression in tlg2Δ yeast resulted in
increased vesicle aggregation (9.04±0.48% in control vs 49.86±3.48% in tlg2Δ, Fig. 3a).
The Tlg2p-deficient mutants were also sensitized to Syn-EGFP expression (Fig. 3b). Finally,
affinity capture mass spectrometry experiments report Ypt6p interacts with Hsp82p (Zhao et
al. 2005), the yeast homolog of mammalian Hsp90. This interaction is irrelevant to the
robustness of Syn-EGFP-dependent vesicle aggregation, however (Fig. 3a).
In summary, we have identified several genes involved in the regulation of endosome–Golgi
fusion that are sensitized to the presence of α-synuclein and have an inhibitory effect on α-
synuclein vesicular aggregation. These genes include Ypt6p and its regulators, Ric1p and
Rgp1p; components of the GARP, Vps51p, Vps52p, Vps53p, and Vps54p, and the t-SNARE
Tlg2p (Fig. 3d).
α-Synuclein Interacts with Acidic Phospholipids to Promote Formation of Vesicle
Aggregations
Previously, we have reported that the formation of α-synuclein-associated vesicle
aggregations nucleates at the plasma membrane and requires the α-synuclein N-terminal
region (Soper et al. 2008). Because this region binds acidic phospholipids (Davidson et al.
1998; Rhoades et al. 2006; Stockl et al. 2008), we compared the localization profiles of α-
synuclein-EGFP and RFP-Spo2051–91. The RFP chimera harbors the phosphatidic acid-
binding region of the Spo20p t-SNARE (Nakanishi et al. 2004). Indeed, α-synuclein-EGFP
and RFP-Spo2051–91 strongly colocalize at the plasma membrane in yeast (Fig. 4a). By
contrast, EGFP is diffusely distributed throughout the cytoplasm (Fig. 4b). Deletion of the
first 57 amino acids of the α-synuclein-EGFP chimera, which removes the first four α-
synuclein lipid-binding repeats, also produces a protein which is diffusely distributed
throughout the cytoplasm.
β-Synuclein-EGFP, which contains an N terminus which resembles that of α-synuclein,
colocalizes with RFP-Spo2051–91 at the plasma membrane but does not support formation of
the large cytoplasmic vesicle aggregations seen induced by α-synuclein expression, most
likely because β-synuclein lacks the hydrophobic NAC domain. Consistent with this
scenario, the Δ71–82-α-synuclein-EGFP (for which the hydrophobic NAC domain is also
deleted) exhibits a localization profile similar to that of β-synuclein. These data confirm our
previous report that the N terminus of α-synuclein is required for lipid binding in the yeast
system. Not surprisingly, this N-terminal region is also required for colocalization with
RFP-Spo2051–91.
Small α-syn-EGFP-enriched domains that form at the plasma membrane colocalize with
RFP-Spo2051–91, suggesting that α-synuclein binding to phosphatidic acid nucleates the
early stages of aggregation. Surprisingly, the larger cytoplasmic vesicle aggregations at later
time points are no longer populated with a detectable pool of RFP-Spo2051–91 (Fig. 4a),
suggesting that these vesicle aggregates are either depleted of phosphatidic acid or these
become enriched in other phospholipids during maturation.
To further examine the role of phosphatidic acid in the formation of α-synuclein-induced
vesicle aggregates, the effects of α-synuclein expression were monitored in several sec14ts
mutants that exhibit increased levels of phosphatidic acid. Sec14p is the major yeast
phosphatidylinosito/phosphatidylcholine transfer protein, and it plays an essential role in
coordinating lipid metabolism with TGN/endosomal membrane dynamics (Salama et al.
1990; Bankaitis et al. 1990; Cleves et al. 1991; Mousley et al. 2008). The normally essential
Sec14p requirement for cell viability is relieved by inactivation of several genes, including
the structural genes for yeast choline kinase (Cleves et al. 1991), and the oxysterol binding
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protein Kes1p (Fang et al. 1996). These cki1 and kes1 mutations require the production of a
phospholipase D-dependent phosphatidic acid pool for manifestation of “bypass Sec14”
phenotypes (Xie et al. 1998). If phosphatidic acid plays an early role in α-synuclein
accumulation in yeast, α-synuclein aggregation phenotypes should be enhanced in these
mutants due to expanded phosphatidic acid pools.
We examined α-synuclein-EGFP aggregation in isogenic sec14ts, sec14ts cki1, and sec14ts
kes1 mutants both at the sec14ts permissive (25°C) and restrictive (37°C) temperatures.
Indeed, α-synuclein-EGFP aggregation was markedly increased in all sec14ts mutants at
both restrictive and permissive temperatures (Fig. 5a). Quantitative analyses revealed
enhanced α-synuclein-EGFP aggregation in sec14ts at 25°C (Fig. 5b, 10.3±1.6% in controls;
21.9±0.9% in sec14ts), and a further two-fold enhancement at 37°C. The kes1 and cki1
“bypass Sec14” mutations failed to alleviate the aggregation phenotype. Rather, the
phenotype was even more robust in the “bypass sec14” mutants at both 25°C (34.9±1.9% in
sec14ts kes1 and 28.9±2.0% in sec14ts cki1) and 37°C (40.8±0 1.7% in sec14ts kes1 and
47.9±2.5% in sec14ts cki1). These data suggest that enhanced α-synuclein-EGFP
aggregation in sec14ts mutants is not a simple consequence of vesicle trafficking defects as
the “bypass Sec14” mutations rescue trafficking defects without alleviating the aggregation
phenotypes. Lipidomic analyses confirmed previous demonstrations that sec14ts and sec14ts
cki1 yeast exhibit elevated bulk cellular phosphatidic acid levels (Xie et al. 1998) and that
phosphatidic acid levels were proportionally increased to the robustness of α-synuclein
aggregation in these mutants at 25°C and 37°C (Fig. 5c).
These data suggest that α-synuclein interacts with phosphatidic acid rich membranes and
that this interaction plays a pivotal role in the disruption of intracellular vesicle trafficking
and development of α-synuclein vesicular aggregations.
Discussion
In this study, we have further characterized the formation of α-synuclein-induced vesicle
aggregations in S. cerevisiae. Here, we have shown that nine of the eleven yeast Rab
GTPases colocalize with these vesicle aggregations, which is surprising considering their
known normal localization to many distinct vesicular structures. These data are supported by
similar findings in a recent study where multiple Rab GTPases were found to colocalize
with α-synuclein in yeast (Gitler et al. 2008). Colocalization of these Rab GTPase proteins
with α-syn in vesicle aggregations suggests that they may be sequestering the Rab GTPases
away from their normal target membranes, which could result in wide-spread deficiencies in
inter-organelle trafficking. The mechanism by which α-synuclein sequesters Rab GTPases to
vesicle aggregations is currently unknown. We were unable to identify a direct physical
interaction between α-synuclein and Rab GTPases, although an interaction between A30P α-
synuclein and Rab3a, Rab5, and Rab8 has been observed in transgenic mice (Dalfo et al.
2004). Given that Rab GTPases cycle on and off membranes (Soldati et al. 1993), their
colocalization with vesicle aggregations may simply be a result of mistargeting to these
vesicles and not a direct interaction with α-synuclein.
We found that deletion of three Rab GTPases, Ypt6p, Ypt7p, and Ypt51p, resulted in an
increase in vesicle aggregations. All three of these Rab GTPases are involved with the
endocytic pathway (Wichmann et al. 1992; Singerkruger et al. 1994; Luo and Gallwitz
2003), suggesting that the vesicles found in these accumulations originate from the
endocytotic pathway. Deletion of Ypt6 in particular resulted in a dramatic increase in vesicle
aggregations and toxicity, which was able to be rescued by expression of RFP-Ypt6p, but
not RFP alone or RFP-Vma4. Furthermore, we demonstrated the ability of overexpressed
Ypt6p to reduce vesicle aggregation in wild type yeast cells.
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To further examine this phenomenon, we expressed α-synuclein in yeast with deletions of
known Ypt6 effector proteins. Deletion of either Ric1p or Rgp1p, GTP exchange factors for
Ypt6p, results in an increase in vesicle aggregation and toxicity, similar to the effect seen in
Ypt6Δ cells. Therefore, functional Ypt6p inhibits the formation or promotes the removal of
α-synuclein-induced vesicle aggregations. Ypt6p regulates retrograde endosome–Golgi
fusion through an interaction with the GARP complex, composed of Vps51p, Vps52p,
Vps53p, and Vps54p (Siniossoglou and Pelham 2002). Deletion of any of these GARP
components results in an increase in vesicle aggregation and toxicity. Interestingly, although
Vps51p is the only GARP component reported to be synthetically lethal with Ypt6p;
Vps51p, Vps52p, and Vps54p caused synthetic lethality with α-synuclein. These data imply
that α-synuclein is not directly inhibiting Ypt6p, as α-synuclein causes synthetic lethality
with different genes than does Ypt6p knockout strain. Our findings suggest that α-synuclein
interferes with an endosome–Golgi trafficking event that is downstream from, but dependent
on, Ypt6p-mediated tethering of endosomes to the Golgi.
Fusion of endosomes with the Golgi requires association of the GARP complex with an
essential Golgi t-SNARE, Tlg1p (Siniossoglou and Pelham 2001; Siniossoglou and Pelham
2002) and another non-essential t-SNARE, Tlg2p (Abeliovich et al. 1999). Deletion of
Tlg2p is not toxic to yeast cells; however, it causes toxicity and massive vesicle aggregation
in yeast expressing α-synuclein. These data suggest that α-synuclein directly interferes with
endosome–Golgi trafficking. α-Synuclein may play a role in the formation of SNARE
complexes, as has been observed in mouse models (Chandra et al. 2005), or antagonize
SNARE function, as has been observed in mammalian cells (Thayanidhi et al. 2010).
We hypothesize that one function of α-synuclein is to regulate vesicular fusion, through an
unknown mechanism. Overexpression of α-synuclein may stall vesicular fusion, and in yeast
this specifically causes massive accumulation of vesicles and toxicity associated with
disruption of endosome–Golgi trafficking. These data are consistent with observations of
increased synaptic vesicle pools in PC12 cells overexpression α-synuclein (Larsen et al.
2006), and the observation that α-synuclein knockout mice have a reduction in both docked
and reserve synaptic vesicle pools in hippocampal neurons (Chandra et al. 2004). α-
Synuclein has also been shown to interfere with exocytosis and synaptic vesicle recycling in
mammalian neurons (Scott et al. 2010; Nemani et al. 2010), which may be the result of a
similar toxic mechanism.
While we observed a specific defect in endosome–Golgi retrograde trafficking in yeast
expressing α-synuclein, we have not ruled out that α-synuclein may cause defects in vesicle
fusion at multiple transport steps. Indeed, it has been reported that expression of α-synuclein
causes deficits in endocytosis in yeast (Outeiro and Lindquist 2003), deficits in ER–Golgi
trafficking (Cooper et al. 2006) and that yeast expressing α-synuclein are sensitive to
disruption of vesicular trafficking (Willingham et al. 2003; Zabrocki et al. 2008). These data
are further supported by the recent observation that disruption of endocytosis in α-synuclein
expressing worms results in severe growth impairments and motor dysfunction (Kuwahara
et al. 2008). These observations support disruption of endocytosis as a possible mechanism
for α-synuclein toxicity.
Cooper et al. have reported that α-synuclein induces carboxypeptidase Y (CPY) and alkaline
phosphatase (ALP) glycosylation defects and that these defects and toxicity can be rescued
by overexpression of the Rab GTPase, Ypt1p. These observations are consistent with
reported phenotypes in yeast harboring a temperature-sensitive Ypt6p mutation. It has been
shown that temperature-sensitive Ypt6p mutants have deficits in CPY and ALP trafficking,
possibly through an inhibition of retrograde transport of glycotransferases and that these
cells can be rescued by overexpression of Ypt1p (Luo and Gallwitz 2003). A specific
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sensitivity to disruption of Ypt1p through overexpression of a dominant-negative form of
the protein in the presence of α-synuclein has been previously reported, indicating that α-
synuclein may affect ER–Golgi trafficking (Cooper et al. 2006). Gitler et al. have reported
α-synuclein-induced deficit in vesicle fusion in a cell-free ER–Golgi transport assay (Gitler
et al. 2008), whereas in this study, we have demonstrated that α-synuclein may interfere
with a fusion event at the endosome–Golgi step. Given α-synuclein’s synaptic localization in
mammals, it is reasonable to assume that α-synuclein can regulate vesicle fusion at the
synapse. The surprising trafficking phenotypes observed in yeast may be due to the
conservation of basic SNARE-mediated vesicle fusion machinery between yeast and
mammals (Kloepper et al. 2007).
In this study, we have further examined the relationship between α-synuclein membrane
localization and accumulation. Significantly, we have found that α-synuclein colocalizes
with the phosphatidic acid marker Spo2051–91 at the plasma membrane and in early
accumulations. Yeast strains that produce increased pools of phosphatidic acid show
increased accumulations. These data may also explain the strong membrane localization and
vesicle aggregation phenotype in yeast, as yeast plasma membrane is particularly enriched
for acidic phospholipids compared to other organelle membranes (Zinser and Daum 1995).
These observations suggest that the known membrane binding properties of α-synuclein may
be important in the early stages of its toxic function in yeast, and that disruption of α-
synuclein phospholipid binding may be a possible therapeutic mechanism for the treatment
of Parkinson’s disease
It is provocative to speculate on the relationship between α-synuclein-induced vesicle
aggregation and neurodegeneration in PD. α-Synuclein fibrillization has long been studied
as a potential pathogenic mechanism, and vesicle content has been observed in Lewy bodies
and pale bodies in PD (Duffy and Tennyson 1965; Forno and Norville 1976; Watanabe et al.
1977; Hayashida et al. 1993; Soper et al. 2008). It is possible that accumulation of vesicles
may serve as a “seed” to induce formation of α-synuclein fibrils and subsequent inclusion
formation, due to the high concentration of α-synuclein in these accumulations.
Alternatively, disruption of trafficking events by α-synuclein could directly cause toxicity in
neurons, particularly in the affected dopaminergic neurons in PD patients. Accumulation of
dopamine-containing vesicles may result in accumulation of potentially toxic dopamine
metabolites, resulting in selective degeneration of dopaminergic neurons (Xu et al. 2002).
Further characterization of the role α-synuclein plays in vesicle tethering and fusion, as well
as the functional consequences of α-synuclein interaction with acidic phospholipids, may
provide important insights into both the normal function and abnormal pathogenic function
of α-synuclein and could reveal new therapeutic targets for the treatment of Parkinson’s
disease.
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α-Synuclein disrupts localization of Rab GTPase proteins in S. cerevisiae. Fluorescence
microscopy of yeast cells expressing RFP-tagged Rab GTPase proteins. RFP alone (a) is
localized to the cytoplasm in yeast expressing EGFP and Syn-EGFP. RFP-Vma4p (b) labels
the vacuole membrane in EGFP and Syn-EGFP cells. Rab GTPase proteins RFP-Sec4p (c),
RFP-Ypt1p (d), RFP-Ypt6p (e), RFP-Ypt7p (f), RFP-Ypt10p (g), RFP-Ypt31p (h), RFP-
Ypt32p (i), RFP-Ypt51p (j), and RFP-Ypt53p (k) all colocalize with Syn-EGFP
accumulations. In cells expressing Syn-EGFP, localization of Ypt10p to the vacuole (arrow)
can be seen in addition to colocalization with vesicle aggregations. Normal Sec4p labeling
can also be seen in addition to colocalization with accumulations (arrow). Scale bar, 2 μM
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Deletion of Ypt6 increases α-synuclein-induced vesicle aggregations and toxicity in S.
cerevisiae. (a) Quantification of vesicle aggregations in yeast knockout strains expressing
Syn-EGFP. Ypt6 knockout yeasts have a significant increase in Syn-EGFP vesicle
aggregations. Error bars indicate SEM *p<0.001. (b) Western blot of extracts from control
and Ypt6 knockout yeast expressing Syn-EGFP. Increased vesicle aggregation was not due
to a change in Syn-EGFP expression level. (c) Quantification of vesicle aggregations in
yeast cells coexpressing Syn-EGFP and RFP, RFP-Vma4p, or RFP-Ypt6p. Expression of
RFP-Ypt6p in Ypt6 knockout yeast restores vesicle aggregation levels back to that of
control. (d) Fluorescence microscopy of yeast coexpressing Syn-EGFP and RFP, RFP-
Vma4p, or RFP-Ypt6p. (e) Deletion of Ypt6 impairs growth of yeast expressing Syn-EGFP,
but not EGFP alone. This effect can be rescued by expression of RFP-Ypt6p, but not RFP or
RFP-Vma4p. (f) Expression of RFP-Ypt6p reduces vesicle aggregation in yeast grown in
5% DMSO. (g) Western blot of extracts from cells expressing Syn-EGFP and RFP or RFP-
Ypt6p. Scale bar, (d) 2 μM
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Ypt6 regulates α-synuclein induced vesicle aggregation through endosome–Golgi retrograde
transport. (a) Quantification of vesicle aggregations in yeast knockout strains. Deletion of
the GTP exchange factor for Ypt6 (Ric1/Rgp1), deletion of components of the Golgi-
associated retrograde protein complex (Vps51/52/Vps54), and deletions of Tlg2p and
Vps35p result in increased vesicle aggregation. Error bars indicate SEM *P<0.001. (b)
Knockout strains that have increased vesicle aggregation cause increased toxicity in cells
expressing Syn-EGFP (right Gal panels), but not EGFP alone (bottom panels). (c) Western
blot on extracts used for quantification. Variations in vesicle aggregation are not due to
differences in Syn-EGFP expression level. (d) Schematic depicting Ypt6 cycling and
endosome–Golgi fusion. Knockouts of Ypt6p, Ric1p, Rgp1p, Vps51p, Vps52p, Vps53p,
Vps54p, and Tlg2p result in a large increase in α-syn-induced vesicle aggregation and
toxicity. Ric1p/Rgp1p are guanine nucleotide exchange factors for Ypt6p. Vps51p/Vps52p/
Vps53p/Vps54p compose the Golgi associated retrograde protein complex (GARP), and
Tlg2p is a t-SNARE involved in endosome–Golgi fusion
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Colocalization of α-Synuclein with the phosphatidic acid marker Spo2051–91 in S.
cerevisiae. (a) Fluorescence microscopy of cells expressing α-synuclein-EGFP and RFP-
Spo2051–91. α-Synuclein-EGFP colocalizes with RFP-Spo2051–91 at the plasma membrane
and in early accumulations. As the accumulations mature to large cytoplasmic
accumulations (lower panels), they no longer colocalize with RFP-Spo2051–91. (b)
Fluorescence microscopy of cells expressing EGFP, 58–140-EGFP, β-synuclein-EGFP, or
Δ71–82-α-syn-EGFP and RFP-Spo2051–91. EGFP and 58–140-EGFP do localize to the
cytoplasm and do not colocalize with RFP-Spo2051–91. β-Synuclein-EGFP and Δ71–82-α-
syn-EGFP colocalize with RFP-Spo2051–91 at the plasma membrane, but do not form large
cytoplasmic accumulations. Scale Bar, (a) 1 μM
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Sec14ts and sec14ts bypass mutants increase α-synuclein accumulation in S. cerevisiae. (a)
Fluorescence images of control, sec14ts, sec14ts kes1, and sec14ts cki1 cells expressing α-
synuclein-EGFP at 25°C and 37°C. (b) Quantification of accumulation formation in control,
sec14ts, sec14ts kes1, and sec14ts cki1 cells. Accumulation did not increase in control cells
when shifted from 25°C to 37°C. Accumulation levels significantly increased in sec14ts,
sec14ts kes1, and sec14ts cki1 strains when shifted from 25°C to 37°C. Sec14ts kes1 and
sec14ts cki1 had higher baseline levels of accumulation than sec14ts and control cells. (c)
Mass spec analysis of phosphatidic acid (PA) in pooled samples of control, sec14ts, and
sec14ts cki1 cells. Sec14ts and sec14ts cki cells had higher levels of PA at 25°C. Shifting
cells to 37°C increased PA levels in all strains. Scale Bar, (a) 2 μM
Soper et al. Page 22
J Mol Neurosci. Author manuscript; available in PMC 2011 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
